A multi-center, randomized, double-blind, placebo-controlled phase IIb was conducted to evaluate the efficacy, safety, pharmacodynamics, pharmacokinetics, and immunogenicity of subcutaneous CM310, an anti-IL-4Rα monoclonal antibody (Figure 3b), for adults with moderate-severe AD subjects. Here, IL4R is linked to Alzheimer disease.